Navigation Links
BioMosaics' Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe
Date:9/10/2007

BURLINGTON, Vt., Sept. 10 /PRNewswire/ -- BioMosaics Inc., a cancer biomarker development company, announced today that it has received CE marking for its proprietary products for the identification of Glypican-3 (GPC3) in human blood and in tissue as in vitro diagnostic tests. This will allow the GPC3 (Human Glypican-3) ELISA Kit for detecting GPC3 in human serum or plasma, and the GPC3 (Human Glypican-3) Monoclonal Antibody (clone 1G12) to detect GPC3 in tissue by immunohistochemistry (IHC), to be marketed in the European Union.

GPC3, an oncofetal antigen, is a member of the glypican family of glycosyl phosphatidylinositol-anchored cell-surface heparan sulfate proteoglycans. The anti-GPC3 monoclonal antibody (MAb; clone 1G12) has also been used to assess GPC3 expression in malignant and non-malignant liver tissue samples and for ELISA detection of GPC3 in the serum. Capurro et al. have shown that GPC3 is expressed at the protein level by immunohistochemistry in most cases of primary liver cancer including small tumors, but is undetectable in normal liver and benign hepatic lesions [Gastroenterology. 2003; 125:89-97]. Three recent major studies using BioMosaics GPC3 MAb have confirmed the early presence of GPC3 on hepatocellular carcinoma (HCC) and highly dysplastic cirrhotic nodules. [Wang XY et al, Human Pathology. 2006; 37(11):1435-41, Libbrecht et al, Am J Surg Pathol. 2006. 30(11):1405-1411, and Di Tommaso, Hepatology. 2007; 45(3):725-34].

Primary Liver Cancer, or Hepatocellular Carcinoma, is one of the most common and aggressive malignant tumors worldwide, causing an estimated one million deaths annually. Over 430,000 new cases of HCC are diagnosed each year. The main causative agents are hepatitis B virus (HBV), hepatitis C virus (HCV), as well as alcoholic cirrhosis and non-alcoholic steatohepatitis (NASH) which is associated with obesity, diabetes, and insulin resistance factors. The incidence of HCC has been steadily increasing over the past ten years and is expected to continue to rise over the next decade.

"BioMosaics recognizes the importance of developing new diagnostic tests that could more effectively target a specific type of cancer in the early stages. We are pleased that we have established these two high quality diagnostic products for the EU," said Dr. Ronald D. Guttmann, Executive VP Clinical Development.

About BioMosaics

BioMosaics is a biotechnology company located in Burlington, VT, engaged in the development and commercialization of innovative products for the early diagnosis, prediction, and monitoring of cancer.

Contacts:

BioMosaics Inc.

http://www.biomosaics.com

Mark Allegretta PhD; m.allegretta@biomosiacs.com

Ronald D. Guttmann MD; r.guttmann@biomosaics.com

+1-802-656-5443

Note: Statements in this news release that are not historical facts are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.


'/>"/>
SOURCE BioMosaics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
5. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
8. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall ... to its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). ... UV disinfection robot that uses UVC light energy to kill deadly pathogens such as ... Tru-D ... Tru-D in action ...
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
Breaking Medicine Technology:
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning firm that serves residential and commercial clients in the greater ... drive to raise community support for the fight against cancer. , Founded by ...
(Date:8/18/2017)... ... 18, 2017 , ... With over 16,000 active patients, BodyLogicMD, ... therapy and integrative medicine, has become a frontrunner for people seeking help with ... andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by Patrick ...
(Date:8/18/2017)... ... August 18, 2017 , ... Inc. magazine has ranked American ... prestigious ranking of the nation's fastest-growing private companies. This marks the eighth time in ... 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue growth from ...
(Date:8/18/2017)... ... 2017 , ... “Dangerous Inheritance”: a mystery about saving the family farm. ... Southwest Nebraska where she was raised on a farm. As Diane wrote this ... but the friendships and mantra of ‘neighbors helping neighbors’ have always been a large ...
(Date:8/18/2017)... ... 18, 2017 , ... “Depressed: Super Heroes of the Bible”: a gripping ... stories and the relevance these tales may have on the reader’s life. “Depressed: Super ... special education teacher, Jessica spends much of her time enjoying nature and her family ...
Breaking Medicine News(10 mins):